Pancreatic Cancer Research

ResearcherNational Cancer Center HospitalActive in the last 2 years

Junki Mizusawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8123-5298; OpenAlex author ID A5039783762. Sources: OpenAlex.

Their work

Papers
6
Trials
0
Grants
0
Labs led
0
Collaborators
55
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 6

  1. Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II t… Co-author DOI 10.1186/s12885-026-15699-8↗
  2. Modified Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin or S-1, Irinotecan, and Oxaliplatin Versus Nab-Paclitaxel + Gemcitabine in Metastatic or Recurre… Co-author DOI 10.1200/jco.24.00936↗
  3. A multi-institutional randomized phase III study comparing minimally invasive distal pancreatectomy versus open distal pancreatectomy for pancreatic cancer; Ja… Co-author DOI 10.1186/s12885-024-11957-9↗
  4. A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407). Co-author DOI 10.1016/j.ejca.2022.12.014↗
  5. Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group… Co-author DOI 10.1093/jjco/hyaa198↗
  6. Protocol digest of randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic … Co-author DOI 10.1016/j.pan.2018.07.007↗

Closest collaborators

The 25 strongest of 55 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 5 shared papers, 2018–2026 · strength 0.64
  2. Masafumi Ikeda · 4 shared papers, 2018–2026 · strength 0.49
  3. Masato Ozaka · 4 shared papers, 2018–2026 · strength 0.49
  4. Junji Furuse · 4 shared papers, 2018–2026 · strength 0.49
  5. Takuji Okusaka · 4 shared papers, 2018–2026 · strength 0.49
  6. Tatsuya Ioka · 3 shared papers, 2018–2026 · strength 0.37
  7. Yusuke Sano · 2 shared papers, 2024–2026 · strength 0.35
  8. Yoshito Komatsu · 2 shared papers, 2023–2026 · strength 0.33
  9. Satoshi Kobayashi · 2 shared papers, 2023–2026 · strength 0.33
  10. Yukiko Takayama · 2 shared papers, 2023–2026 · strength 0.33
  11. Ken Kamata · 2 shared papers, 2023–2026 · strength 0.33
  12. Nao Fujimori · 2 shared papers, 2023–2026 · strength 0.33
  13. Naoki Sasahira · 2 shared papers, 2023–2026 · strength 0.33
  14. Satoaki Nakamura · 2 shared papers, 2021–2026 · strength 0.29
  15. Nobumasa Mizuno · 3 shared papers, 2018–2023 · strength 0.29
  16. Hiroshi Ishii · 3 shared papers, 2018–2023 · strength 0.29
  17. Naohiro Okano · 2 shared papers, 2021–2023 · strength 0.22
  18. Akiko Todaka · 2 shared papers, 2021–2023 · strength 0.22
  19. Kentaro Yamazaki · 1 shared paper, 2026 · strength 0.20
  20. Taro Yamashita · 1 shared paper, 2026 · strength 0.20
  21. Kazuo Hara · 1 shared paper, 2026 · strength 0.20
  22. Fumio Nagashima · 1 shared paper, 2026 · strength 0.20
  23. Masashi Kanai · 1 shared paper, 2026 · strength 0.20
  24. Shin Maeda · 1 shared paper, 2026 · strength 0.20
  25. Kazuyoshi Ohkawa · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.